ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) Stock Fundamental Analysis
USA - NASDAQ:ZYBT - KYG989MS1016 - Common Stock
2.17 USD
-0.03 (-1.36%)
ZYBT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here. ZYBT is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ZYBT had positive earnings in the past year.
In the past year ZYBT had a positive cash flow from operations.
1.2 Ratios
ZYBT's Return On Assets of 7.96% is amongst the best of the industry. ZYBT outperforms 89.06% of its industry peers.
ZYBT's Return On Equity of 13.83% is amongst the best of the industry. ZYBT outperforms 88.54% of its industry peers.
ZYBT has a better Return On Invested Capital (12.67%) than 91.15% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZYBT is below the industry average of 13.75%.
The last Return On Invested Capital (12.67%) for ZYBT is above the 3 year average (10.57%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROIC | 12.67% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
1.3 Margins
ZYBT's Profit Margin of 12.95% is amongst the best of the industry. ZYBT outperforms 86.46% of its industry peers.
ZYBT's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 16.66%, ZYBT belongs to the top of the industry, outperforming 85.42% of the companies in the same industry.
In the last couple of years the Operating Margin of ZYBT has declined.
ZYBT has a Gross Margin of 54.00%. This is in the better half of the industry: ZYBT outperforms 64.06% of its industry peers.
In the last couple of years the Gross Margin of ZYBT has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% |
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ZYBT is creating some value.
Compared to 1 year ago, ZYBT has about the same amount of shares outstanding.
Compared to 1 year ago, ZYBT has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.40 indicates that ZYBT is not in any danger for bankruptcy at the moment.
ZYBT's Altman-Z score of 3.40 is fine compared to the rest of the industry. ZYBT outperforms 71.88% of its industry peers.
The Debt to FCF ratio of ZYBT is 6.51, which is on the high side as it means it would take ZYBT, 6.51 years of fcf income to pay off all of its debts.
ZYBT's Debt to FCF ratio of 6.51 is amongst the best of the industry. ZYBT outperforms 80.21% of its industry peers.
ZYBT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
ZYBT has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: ZYBT outperforms 55.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Altman-Z | 3.4 |
ROIC/WACC1.6
WACC7.9%
2.3 Liquidity
A Current Ratio of 1.31 indicates that ZYBT should not have too much problems paying its short term obligations.
ZYBT's Current ratio of 1.31 is on the low side compared to the rest of the industry. ZYBT is outperformed by 75.00% of its industry peers.
A Quick Ratio of 0.88 indicates that ZYBT may have some problems paying its short term obligations.
With a Quick ratio value of 0.88, ZYBT is not doing good in the industry: 80.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.94% over the past year.
Measured over the past years, ZYBT shows a very strong growth in Earnings Per Share. The EPS has been growing by 528.02% on average per year.
Looking at the last year, ZYBT shows a very strong growth in Revenue. The Revenue has grown by 43.18%.
The Revenue has been growing by 854.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.08 indicates a rather expensive valuation of ZYBT.
Compared to the rest of the industry, the Price/Earnings ratio of ZYBT indicates a rather cheap valuation: ZYBT is cheaper than 82.81% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.89, ZYBT is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.08 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZYBT indicates a rather cheap valuation: ZYBT is cheaper than 86.46% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ZYBT is valued a bit cheaper than 76.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.98 | ||
| EV/EBITDA | 10.78 |
4.3 Compensation for Growth
The decent profitability rating of ZYBT may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ZYBT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ZYBT (11/17/2025, 3:06:49 PM)
2.17
-0.03 (-1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.89%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap102.84M
Revenue(TTM)303.21M
Net Income(TTM)39.27M
AnalystsN/A
Price TargetN/A
Short Float %3.93%
Short Ratio0.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.08 | ||
| Fwd PE | N/A | ||
| P/S | 2.41 | ||
| P/FCF | 54.98 | ||
| P/OCF | 17.78 | ||
| P/B | 2.57 | ||
| P/tB | 2.79 | ||
| EV/EBITDA | 10.78 |
EPS(TTM)0.12
EY5.53%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY1.82%
OCF(TTM)0.12
OCFY5.62%
SpS0.9
BVpS0.84
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROCE | 14.13% | ||
| ROIC | 12.67% | ||
| ROICexc | 13.42% | ||
| ROICexgc | 14.4% | ||
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% | ||
| FCFM | 4.38% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3Y-33.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 114.94% | ||
| Cap/Sales | 9.16% | ||
| Interest Coverage | 12.67 | ||
| Cash Conversion | 54.97% | ||
| Profit Quality | 33.8% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 3.4 |
F-Score7
WACC7.9%
ROIC/WACC1.6
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A
ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ
What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT.
Can you provide the valuation status for ZHENGYE BIOTECHNOLOGY HOLDIN?
ChartMill assigns a valuation rating of 4 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Fairly Valued.
What is the profitability of ZYBT stock?
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 6 / 10.
Can you provide the financial health for ZYBT stock?
The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 5 / 10.